These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 28148228

  • 1. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.
    BMC Public Health; 2017 Feb 02; 17(1):152. PubMed ID: 28148228
    [Abstract] [Full Text] [Related]

  • 2. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 3. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA, Lepetic A, Demarteau N.
    BMC Public Health; 2014 Nov 26; 14():1222. PubMed ID: 25424716
    [Abstract] [Full Text] [Related]

  • 4. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 5. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH, Cheng WF, Jiang JH, You SL, Huang LW, Hsieh JY, Mukherjee P, Van Kriekinge G, Lee C.
    Asian Pac J Cancer Prev; 2019 May 25; 20(5):1377-1387. PubMed ID: 31127896
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 May 25; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.
    Curr Med Res Opin; 2008 May 25; 24(5):1473-83. PubMed ID: 18413014
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X, Stander MP, Van Kriekinge G, Demarteau N.
    BMC Infect Dis; 2015 Dec 11; 15():566. PubMed ID: 26652918
    [Abstract] [Full Text] [Related]

  • 12. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, Chow EPF, Xu X, Zhang L, Zhuang G.
    Lancet Glob Health; 2020 Oct 11; 8(10):e1335-e1344. PubMed ID: 32971056
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L, Rémy V, Oyee J, Largeron N.
    Pharmacoeconomics; 2009 Oct 11; 27(3):231-45. PubMed ID: 19354343
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK, Lee BW, Sohn WY, Lee IH, Mathur G, Sanicas M, Van Kriekinge G.
    Singapore Med J; 2018 Jul 11; 59(7):370-382. PubMed ID: 28983579
    [Abstract] [Full Text] [Related]

  • 15. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.
    BMC Infect Dis; 2013 Feb 07; 13():75. PubMed ID: 23390964
    [Abstract] [Full Text] [Related]

  • 16. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G, Sohn WY, Aljunid SM, Soon R, Yong CM, Chen J, Lee IH.
    Asian Pac J Cancer Prev; 2018 Apr 25; 19(4):933-940. PubMed ID: 29693347
    [Abstract] [Full Text] [Related]

  • 17. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
    Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, Taneepanichskul S.
    Value Health; 2012 Apr 25; 15(1 Suppl):S29-34. PubMed ID: 22265063
    [Abstract] [Full Text] [Related]

  • 18. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
    Jit M, Chapman R, Hughes O, Choi YH.
    BMJ; 2011 Sep 27; 343():d5775. PubMed ID: 21951758
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.
    Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW.
    PLoS One; 2013 Sep 27; 8(11):e80639. PubMed ID: 24260441
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Sep 27; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.